'%2F%3E%3Cpath%20d%3D'M11%205H21M13.5%205V11.6A8.5%208.5%200%201%200%2018.5%2011.6V5'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'3.4'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Cpath%20d%3D'M10.6%2019.6L13.9%2021.8L17.6%2018.4L21.4%2020.4'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'2.6'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Ccircle%20cx%3D'17.6'%20cy%3D'18.4'%20r%3D'2.6'%20fill%3D'%23fff'%2F%3E%3C%2Fsvg%3E){kind=small}
Beta Drugs Limited
BETA (NSE) · BETA (BSE 203739) · ISIN INE351Y01019 · Pharmaceuticals · listed 2025
In Q2 FY27 (quarter to 30 September 2026, standalone), revenue was ₹58.01 cr and profit after tax ₹3.71 cr.
Open the full company file Every section, filings and your notes, in the app.
Quarterly results
| Quarter | Revenue | Profit after tax | EPS (₹) | Filed |
|---|---|---|---|---|
| Q2 FY27 standalone | ₹58.01 cr | ₹3.71 cr | 3.29 | 22 Oct 2026 |
| Q1 FY27 standalone | ₹55.83 cr | ₹5.93 cr | 5.55 | 20 Jul 2026 |
| Q4 FY26 standalone | ₹54.35 cr | ₹5.33 cr | 5.26 | 14 May 2026 |
| Q3 FY26 standalone | ₹50.28 cr | ₹3.25 cr | 3.21 | 14 Feb 2026 |
| Q2 FY25 standalone | ₹118.19 cr | ₹13.29 cr | 13.82 | 7 Nov 2024 |
Balance sheet
| As of | Total equity | Borrowings | Total assets |
|---|---|---|---|
| 30 Sep 2026 standalone | ₹317.78 cr | ₹21.21 cr | ₹398.22 cr |
| 31 Mar 2026 standalone | ₹149.56 cr | ₹130.39 cr | ₹334.96 cr |
| 30 Sep 2025 standalone | ₹134.79 cr | ₹133.4 cr | ₹339.03 cr |
Shareholding
| Promoter | FII | DII | Public |
|---|---|---|---|
| 58.91% | 1.37% | 6.45% | 41.09% |
Latest filings
- Beta Drugs Limited has informed the Exchange about Link of Recording 22 October 2026 · NSE
- Beta Drugs Limited has informed the Exchange about Presentation 22 October 2026 · NSE
- Beta Drugs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 22 October 2026 · NSE
- Annual Report FY2025-26 (New) 5 September 2026 · NSE
- Beta Drugs Limited has informed the Exchange about Investor Presentation 27 July 2026 · NSE
Other companies in Pharmaceuticals
- Lupin Limited
- Sun Pharmaceutical Industries Limited
- Torrent Pharmaceuticals Limited
- Zydus Lifesciences Limited
- Ajanta Pharma Limited
- Alivus Life Sciences Limited
- Wockhardt Limited
- Morepen Laboratories Limited
Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 22 October 2026.
Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.